Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort

Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort

Blaise K Kutala,1,2 Feryel Mouri,1 Corinne Castelnau,1 Valerie Bouton,1 Nathalie Giuily,1 Nathalie Boyer,1 Tarik Asselah,1,2 Patrick Marcellin1,2 1Service d’hépatologie, Hopital Beaujon-APHP, 2INSERM – University of Paris Diderot, Paris, France Background: The combinat...

Full description

Bibliographic Details
Main Authors:	Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, Asselah T, Marcellin P
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-12-01
Series:	Hepatic Medicine : Evidence and Research
Subjects:	Sofosbuvir hepatitis C virus interferon-free therapies cirrhosis advanced fibrosis
Online Access:	https://www.dovepress.com/efficacy-and-safety-of-sofosbuvir-based-therapies-in-patients-with-adv-peer-reviewed-article-HMER

Similar Items

Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
by: Carlo Smirne, et al.
Published: (2021-08-01)

Sofosbuvir in therapy of chronic HCV-infection
by: C. S. Pavlov, et al.
Published: (2016-12-01)

TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR
by: Y. O. SHULPEKOVA, et al.
Published: (2017-05-01)

Efficacy of Combination Sofosbuvir, Pegylated-Interferon, and Ribavirin for Treatment of Hepatitis C Virus Genotype 1 Infection in Indonesia
by: Andri Sanityoso Sulaiman, et al.
Published: (2018-08-01)

Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan
by: Yu-Ting Huang, et al.
Published: (2021-06-01)

Treatment Efficacy of Sofosbuvir and Ribavirin Combination at Two Weeks in Chronic Hepatitis C
by: Aqsa Naseer
Published: (2017-12-01)

THE EVOLUTION OF LIVER FIBROSIS AFTER THE TREATMENT WITH DIRECT-ACTING ANTIVIRAL AGENTS IN HEPATIC CIRRHOSIS: EXPERIENCE OF A CENTER
by: Mariana Avricenco, et al.
Published: (2020-10-01)

Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience
by: Bandar Al-Judaibi, et al.
Published: (2018-05-01)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
by: Andrew Hill, et al.
Published: (2016-01-01)

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
by: Mohamed G. Mohamed, et al.
Published: (2021-01-01)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020-09-01)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
by: Phil McEwan, et al.
Published: (2017-07-01)

Safety and efficacy of combination therapy (Simeprevir/Sofosbuvir) in the treatment of chronic HCV genotype IV patients
by: Engy A. Wahsh, et al.
Published: (2018-03-01)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
by: Mohammed A Babatin, et al.
Published: (2019-01-01)

Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study
by: Fanpu Ji, et al.
Published: (2017-09-01)

Noninvasive assessment of hepatic fibrosis regression in hepatitis C virus-infected patients treated with sofosbuvir-based therapy
by: Ahmed Al-Khattib, et al.
Published: (2019-01-01)

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
by: Young Min Kim, et al.
Published: (2018-09-01)

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study
by: Stefan Bourgeois, et al.
Published: (2020-01-01)

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study
by: Masanori Atsukawa, et al.
Published: (2020-09-01)

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study
by: Phunchai Charatcharoenwitthaya, et al.
Published: (2020-03-01)

INTERFERON-FREE THERAPY FOR HEPATITIS C IN PAKISTAN
by: Dure Nayab, et al.
Published: (2017-03-01)

Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis
by: Hee Yeon Seo, et al.
Published: (2020-05-01)

Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care
by: Seong Hee Kang, et al.
Published: (2021-01-01)

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
by: Hyun Phil Shin, et al.
Published: (2017-12-01)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
by: Umer Ansari, BS, et al.
Published: (2017-01-01)

SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3
by: Arif Qayyum Khan, et al.
Published: (2021-02-01)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
by: Eiichi Ogawa, et al.
Published: (2020-09-01)

A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy, Ascites, and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir
by: Kazuo Tarao, et al.
Published: (2021-04-01)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
by: Walker DR, et al.
Published: (2015-12-01)

Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan
by: Hung-Chih Chiu, et al.
Published: (2021-03-01)

Use of sofosbuvir in chronic kidney disease: Is it necessary?
by: Tae Seop Lim, et al.
Published: (2017-12-01)

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort
by: Anne Laurain, et al.
Published: (2019-04-01)

Assessment of auditory functions in chronic hepatitis C patients treated by sofosbuvir
by: Elshahat Ibrahem Ismail, et al.
Published: (2018-03-01)

Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study
by: Oidov Baatarkhuu, et al.
Published: (2021-01-01)

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
by: Heidar Sharafi, et al.
Published: (2020-01-01)

Effectiveness of Sofosbuvir regime in Hepatitis C virus infection in hemodialysis Pakistani patients: Single Centre Study
by: Rahmat Ali Khan, et al.
Published: (2017-12-01)

Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre study
by: B Kirushnan, et al.
Published: (2016-01-01)

Ledipasvir and sofosbuvir for treatment of post- renal transplant hepatitis C infection: A case report withreview of literature
by: R Jha, et al.
Published: (2016-01-01)

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis
by: Mohammad Saeid Rezaee-Zavareh, et al.
Published: (2017-03-01)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
by: Mir F, et al.
Published: (2017-02-01)